ArticleScientific reports2026
One-year prospective study of a HEMA-based hydrophobic acrylic trifocal IOL (Clareon PanOptix): visual performance, patient-reported outcomes, and optic clarity.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Visual Outcomes and Patient-Reported Dysphotopsia After PanOptix and PanOptix Toric Implantation Stratified by Preoperative Chord Mu: A Prospective Observational Cohort Study.Ophthalmology and therapy · 2026Article
- A Comparative Study of the Visual Outcomes of Two Common Diffractive Trifocal Intraocular Lenses in a Matched Cohort.Cureus · 2026Article
- A One-Year Visual and Safety Evaluation of a Newly Available Trifocal Intraocular Lens in Patients With Bilateral Cataracts: Clinical Outcomes From a Prospective Study.Journal of ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While Clareon monofocal intraocular lens (IOL) has been reported to be free from surface light scattering and glistenings, it remains unknown whether Clareon PanOptix IOL develops these optical phenomena. This study aimed to evaluate one-year surgical outcomes of this IOL, with a focus on visual function, patient-reported satisfaction, and clarity of IOL optics. A prospective study was conducted in 78 eyes of 39 patients undergoing bilateral implantation of toric or non-toric Clareon PanOptix IOLs. Postoperative examinations were conducted at 1, 6, and 12 months. At 12 months, bilateral uncorrected visual acuity (BUCVA) and bilateral distance-corrected visual acuity (BDCVA) were better than 20/20 at 40 cm, 60 cm, and 5 m. No cases of surface light scattering or glistenings were observed. Spectacle independence was achieved in 84.2% of patients. While patient satisfaction with vision in daily life and daytime driving was high, approximately half of the patients reported some difficulty with night driving. The Clareon PanOptix provided satisfactory surgical outcomes, with no formation of surface light scattering or glistenings during the one-year follow-up period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.